Skip to main content

Table 2 EULAR (CRP) response rate and SDAI, CDAI, DAS28 (CRP), and Boolean remission rates up to week 24 (ITT population)

From: Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

  CT-P17 (N = 324) EU-adalimumab (N = 324)
EULAR (CRP) response, n (%)
 Week 2
  Good response 22 (6.8) 13 (4.0)
  Moderate response 154 (47.5) 139 (42.9)
 Week 4
  Good response 72 (22.2) 68 (21.0)
  Moderate response 162 (50.0) 167 (51.5)
 Week 8
  Good response 133 (41.0) 123 (38.0)
  Moderate response 143 (44.1) 144 (44.4)
 Week 12
  Good response 162 (50.0) 165 (50.9)
  Moderate response 131 (40.4) 124 (38.3)
 Week 16
  Good response 181 (55.9) 174 (53.7)
  Moderate response 112 (34.6) 109 (33.6)
 Week 20
  Good response 202 (62.3) 201 (62.0)
  Moderate response 91 (28.1) 87 (26.9)
 Week 24
  Good response 208 (64.2) 208 (64.2)
  Moderate response 86 (26.5) 81 (25.0)
CDAI remission rate, n (%)
 Week 2 2 (0.6) 2 (0.6)
 Week 4 11 (3.4) 11 (3.4)
 Week 8 21 (6.5) 24 (7.4)
 Week 12 47 (14.5) 42 (13.0)
 Week 16 51 (15.7) 63 (19.4)
 Week 20 69 (21.3) 85 (26.2)
 Week 24 82 (25.3) 86 (26.5)
SDAI remission rate, n (%)
 Week 2 2 (0.6) 2 (0.6)
 Week 4 12 (3.7) 12 (3.7)
 Week 8 22 (6.8) 22 (6.8)
 Week 12 47 (14.5) 44 (13.6)
 Week 16 53 (16.4) 65 (20.1)
 Week 20 69 (21.3) 87 (26.9)
 Week 24 86 (26.5) 93 (28.7)
DAS28 (CRP) remission rate, n (%)
 Week 2 11 (3.4) 10 (3.1)
 Week 4 32 (9.9) 38 (11.7)
 Week 8 67 (20.7) 68 (21.0)
 Week 12 109 (33.6) 107 (33.0)
 Week 16 128 (39.5) 118 (36.4)
 Week 20 150 (46.3) 146 (45.1)
 Week 24 158 (48.8) 157 (48.5)
Boolean remission rate, n (%)
 Week 2 2 (0.6) 2 (0.6)
 Week 4 9 (2.8) 10 (3.1)
 Week 8 17 (5.2) 17 (5.2)
 Week 12 32 (9.9) 33 (10.2)
 Week 16 40 (12.3) 56 (17.3)
 Week 20 56 (17.3) 66 (20.4)
 Week 24 58 (17.9) 68 (21.0)
  1. Note: There were no significant differences between the CT-P17 and EU-adalimumab groups for any parameter (p > 0.05)
  2. CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, EU-adalimumab European Union-approved adalimumab, EULAR European League Against Rheumatism, SDAI Simplified Disease Activity Index